Dr. Burris on the Exploration of PARP Inhibitors in TNBC

Video

In Partnership With:

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the exploration of PARP inhibitors in triple-negative breast cancer (TNBC).

The competition among the various PARP inhibitors under exploration makes for exciting clinical trials, according to Burris. Several efforts are being made to integrate these biologics into the treatment of patients with diseases such as TNBC. PARP inhibitors are very effective in those who have inherited or acquired BRCA-type mutations, or those who have homologous recombination repair deficiency.

Molecular profiling with next-generation sequencing is increasingly being used to identify these patients who are likely to achieve benefit from the addition of PARP inhibitors, adds Burris. The agents have been fairly well tolerated. Several approaches are examining the addition of PARP inhibitors to the TNBC treatment armamentarium, concludes Burris.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute